New Research Underscores Importance of Molecular Testing in Atopic Dermatitis Treatment Choices#None#Atopic_Dermatitis#Castle_Biosciences#AdvanceAD-Tx#Friendwood
New Research Underscores Importance of Molecular Testing in Atopic Dermatitis Treatment Choices
Recent findings reveal a significant patient demand for molecular testing in guiding effective treatments for atopic dermatitis, enhancing care decisions.
third-news.com
September 24, 2026 at 8:40 PM
New Research Underscores Importance of Molecular Testing in Atopic Dermatitis Treatment Choices#None#Atopic_Dermatitis#Castle_Biosciences#AdvanceAD-Tx#Friendwood
Sanofi Releases Important White Paper on Atopic Dermatitis and Employment#Japan#Tokyo#Atopic_Dermatitis#Sanofi#Employment_Impact
Sanofi Releases Important White Paper on Atopic Dermatitis and Employment
Sanofi's latest white paper investigates the impact of atopic dermatitis on employment and career formation, shedding light on the struggles faced by patients.
third-news.com
June 18, 2026 at 7:05 AM
Sanofi Releases Important White Paper on Atopic Dermatitis and Employment#Japan#Tokyo#Atopic_Dermatitis#Sanofi#Employment_Impact
New Study on Early Flare Prediction in Atopic Dermatitis Begins with Patient Enrollment#Sweden#Stockholm#Atopic_Dermatitis#SciBase#Castle_Biosciences
New Study on Early Flare Prediction in Atopic Dermatitis Begins with Patient Enrollment
SciBase and Castle Biosciences initiate a groundbreaking study to predict flares in atopic dermatitis, enhancing patient care.
third-news.com
June 10, 2026 at 7:20 AM
New Study on Early Flare Prediction in Atopic Dermatitis Begins with Patient Enrollment#Sweden#Stockholm#Atopic_Dermatitis#SciBase#Castle_Biosciences
New Study Reveals Nevisense's Promise in Predicting Atopic Dermatitis in Infants#Sweden#Stockholm#Atopic_Dermatitis#Nevisense#SciBase
New Study Reveals Nevisense's Promise in Predicting Atopic Dermatitis in Infants
A recent study demonstrates the potential of Nevisense technology in identifying infants at risk of developing atopic dermatitis, paving the way for early intervention strategies.
third-news.com
June 9, 2026 at 2:19 PM
New Study Reveals Nevisense's Promise in Predicting Atopic Dermatitis in Infants#Sweden#Stockholm#Atopic_Dermatitis#Nevisense#SciBase
Eli Lilly's EBGLYSS™ Receives FDA Approval for New Atopic Dermatitis Treatment Regimen#United_States#Indianapolis#Atopic_Dermatitis#Eli_Lilly#EBGLYSS
Eli Lilly's EBGLYSS™ Receives FDA Approval for New Atopic Dermatitis Treatment Regimen
Eli Lilly's EBGLYSS has gained FDA approval for a new maintenance dosing schedule, offering patients with atopic dermatitis less frequent injections.
third-news.com
June 9, 2026 at 10:21 PM
Eli Lilly's EBGLYSS™ Receives FDA Approval for New Atopic Dermatitis Treatment Regimen#United_States#Indianapolis#Atopic_Dermatitis#Eli_Lilly#EBGLYSS
Lynk Pharmaceuticals Achieves Breakthrough Results in Phase III Trial of Zemprocitinib for Atopic Dermatitis#China#Shanghai#Atopic_Dermatitis#Lynk_Pharmaceuticals#Zemprocitinib
Lynk Pharmaceuticals Achieves Breakthrough Results in Phase III Trial of Zemprocitinib for Atopic Dermatitis
Lynk Pharmaceuticals has announced promising topline results from its Phase III trial of zemprocitinib, aimed at treating moderate-to-severe atopic dermatitis, demonstrating significant efficacy and safety.
third-news.com
March 2, 2026 at 12:22 PM
Lynk Pharmaceuticals Achieves Breakthrough Results in Phase III Trial of Zemprocitinib for Atopic Dermatitis#China#Shanghai#Atopic_Dermatitis#Lynk_Pharmaceuticals#Zemprocitinib
EADV Congress 2025 Highlights: Atopic Dermatitis Linked to Increased Suicidal Thoughts#Paris#France#mental_health#Atopic_Dermatitis#EADV_Congress_2025
EADV Congress 2025 Highlights: Atopic Dermatitis Linked to Increased Suicidal Thoughts
A groundbreaking study presented at the EADV Congress 2025 reveals a startling link between atopic dermatitis and suicidal thoughts in adults, stressing the need for mental health awareness.
third-news.com
September 16, 2025 at 10:11 PM
EADV Congress 2025 Highlights: Atopic Dermatitis Linked to Increased Suicidal Thoughts#Paris#France#mental_health#Atopic_Dermatitis#EADV_Congress_2025
SciBase Launches Groundbreaking Study for Early Flare Prediction in Atopic Dermatitis Using AI Technology#Sweden#Stockholm#Atopic_Dermatitis#Nevisense#SciBase
SciBase Launches Groundbreaking Study for Early Flare Prediction in Atopic Dermatitis Using AI Technology
SciBase has enrolled its first patient in a pioneering study aimed at predicting flares in atopic dermatitis using advanced AI techniques. This study marks a crucial step toward proactive skincare.
third-news.com
June 10, 2026 at 7:10 AM
SciBase Launches Groundbreaking Study for Early Flare Prediction in Atopic Dermatitis Using AI Technology#Sweden#Stockholm#Atopic_Dermatitis#Nevisense#SciBase
Simcere's Breakthrough IL-2 Mutant Protein SIM0278 Advances to Phase II Trials#China#Hangzhou#Atopic_Dermatitis#Simcere#SIM0278
Simcere's Breakthrough IL-2 Mutant Protein SIM0278 Advances to Phase II Trials
Simcere Pharmaceutical Group has announced that its mutant IL-2 fusion protein, SIM0278, has entered Phase II clinical trials for the treatment of moderate to severe atopic dermatitis.
third-news.com
November 11, 2025 at 11:45 AM
Simcere's Breakthrough IL-2 Mutant Protein SIM0278 Advances to Phase II Trials#China#Hangzhou#Atopic_Dermatitis#Simcere#SIM0278
Nektar Therapeutics Shares Promising Phase 2b Results for Rezpegaldesleukin in Atopic Dermatitis#United_States#San_Francisco#Atopic_Dermatitis#Nektar_Therapeutics#Razpegaldesleukin
Nektar Therapeutics Shares Promising Phase 2b Results for Rezpegaldesleukin in Atopic Dermatitis
Nektar Therapeutics has released encouraging findings from a Phase 2b trial of rezpegaldesleukin for atopic dermatitis, published in The Lancet.
third-news.com
August 25, 2026 at 12:46 PM
Nektar Therapeutics Shares Promising Phase 2b Results for Rezpegaldesleukin in Atopic Dermatitis#United_States#San_Francisco#Atopic_Dermatitis#Nektar_Therapeutics#Razpegaldesleukin
Understanding the Mechanism Behind Atopic March: IL-13 and Dendritic Cell Interaction#Japan#Tokyo#Atopic_Dermatitis#Dendritic_Cells#IL-13
Understanding the Mechanism Behind Atopic March: IL-13 and Dendritic Cell Interaction
New research identifies the critical roles of IL-13 and specific dendritic cells in the progression of atopic march, linking skin conditions to systemic allergies.
third-news.com
August 24, 2026 at 1:47 AM
Understanding the Mechanism Behind Atopic March: IL-13 and Dendritic Cell Interaction#Japan#Tokyo#Atopic_Dermatitis#Dendritic_Cells#IL-13
Evolved By Nature Receives FDA Clearance for New Atopic Dermatitis Treatment Based on Innovative Peptide Platform#United_States#Needham#Atopic_Dermatitis#Evolved_By_Nature#New_Day
Evolved By Nature Receives FDA Clearance for New Atopic Dermatitis Treatment Based on Innovative Peptide Platform
Evolved By Nature announces the FDA clearance of New Day™ Skin Spray, a topical therapy for atopic dermatitis, marking a significant milestone in peptide-based treatments.
third-news.com
August 20, 2026 at 1:40 PM
Evolved By Nature Receives FDA Clearance for New Atopic Dermatitis Treatment Based on Innovative Peptide Platform#United_States#Needham#Atopic_Dermatitis#Evolved_By_Nature#New_Day
Bambusa Therapeutics Unveils Exciting Preliminary Results for BBT001 in Atopic Dermatitis Treatment#United_States#Boston#Atopic_Dermatitis#Bambusa_Therapeutics#BBT001
Bambusa Therapeutics Unveils Exciting Preliminary Results for BBT001 in Atopic Dermatitis Treatment
Bambusa Therapeutics has reported groundbreaking preliminary results for BBT001, showcasing significant improvements in treating atopic dermatitis.
third-news.com
July 27, 2026 at 10:09 AM
Bambusa Therapeutics Unveils Exciting Preliminary Results for BBT001 in Atopic Dermatitis Treatment#United_States#Boston#Atopic_Dermatitis#Bambusa_Therapeutics#BBT001
Nektar Therapeutics Launches Phase 3 Trials for Novel Atopic Dermatitis Treatment#USA#San_Francisco#Atopic_Dermatitis#Nektar_Therapeutics#Rezpegaldesleukin
Nektar Therapeutics Launches Phase 3 Trials for Novel Atopic Dermatitis Treatment
Nektar Therapeutics begins Phase 3 trials for rezpegaldesleukin, a novel treatment for moderate-to-severe atopic dermatitis to improve patient outcomes.
third-news.com
July 21, 2026 at 11:15 AM
Nektar Therapeutics Launches Phase 3 Trials for Novel Atopic Dermatitis Treatment#USA#San_Francisco#Atopic_Dermatitis#Nektar_Therapeutics#Rezpegaldesleukin
Devonian Health Group Launches Pediatric Clinical Trial for Thykamine™ atopic dermatitis Treatment#Canada#Quebec#Atopic_Dermatitis#Devonian_Health#Thykamine™
Devonian Health Group Launches Pediatric Clinical Trial for Thykamine™ atopic dermatitis Treatment
Devonian Health Group has secured permission from Health Canada to start a Phase II/III clinical trial on Thykamine™, targeting mild-to-moderate atopic dermatitis in children aged 3 months to 17 years. The study aims to evaluate efficacy and safety.
third-news.com
July 21, 2026 at 12:56 PM
Devonian Health Group Launches Pediatric Clinical Trial for Thykamine™ atopic dermatitis Treatment#Canada#Quebec#Atopic_Dermatitis#Devonian_Health#Thykamine™
Castle Biosciences Gains New York Approval for AdvanceAD-Tx Test for Atopic Dermatitis#United_States#New_York#Atopic_Dermatitis#Castle_Biosciences#AdvanceAD-Tx
Castle Biosciences Gains New York Approval for AdvanceAD-Tx Test for Atopic Dermatitis
Castle Biosciences has received approval from New York's Department of Health for its non-invasive AdvanceAD-Tx test, aiding systemic therapy decisions in atopic dermatitis patients.
third-news.com
July 14, 2026 at 8:40 PM
Castle Biosciences Gains New York Approval for AdvanceAD-Tx Test for Atopic Dermatitis#United_States#New_York#Atopic_Dermatitis#Castle_Biosciences#AdvanceAD-Tx
New Insights on Pediatric Atopic Dermatitis Treatments for Parents of Affected Children in 2026#Japan#Pediatric_Care#Tokyo#Atopic_Dermatitis#Sanofi
New Insights on Pediatric Atopic Dermatitis Treatments for Parents of Affected Children in 2026
A recent survey reveals key insights into treatment preferences for children with atopic dermatitis, emphasizing the importance of healthcare communication.
third-news.com
June 29, 2026 at 4:30 AM
New Insights on Pediatric Atopic Dermatitis Treatments for Parents of Affected Children in 2026#Japan#Pediatric_Care#Tokyo#Atopic_Dermatitis#Sanofi
Triveni Bio Secures $65 Million to Propel Innovative Bispecific TRIV-573 Clinical Studies and Company Expansion#United_States#Atopic_Dermatitis#Watertown#Triveni_Bio#TRIV-573
Triveni Bio Secures $65 Million to Propel Innovative Bispecific TRIV-573 Clinical Studies and Company Expansion
Triveni Bio has raised $65 million in Series C funding to advance its bispecific antibody clinical studies and enhance company growth, targeting atopic dermatitis.
third-news.com
June 17, 2026 at 11:12 AM
Triveni Bio Secures $65 Million to Propel Innovative Bispecific TRIV-573 Clinical Studies and Company Expansion#United_States#Atopic_Dermatitis#Watertown#Triveni_Bio#TRIV-573
New Study Reveals Nevisense as a Promising Tool for Early Prediction of Atopic Dermatitis in Infants#Atopic_Dermatitis#Nevisense#SciBase
New Study Reveals Nevisense as a Promising Tool for Early Prediction of Atopic Dermatitis in Infants
A groundbreaking study highlights Nevisense as a reliable method for early detection of atopic dermatitis, published in the journal Allergy.
third-news.com
June 9, 2026 at 2:21 PM
New Study Reveals Nevisense as a Promising Tool for Early Prediction of Atopic Dermatitis in Infants#Atopic_Dermatitis#Nevisense#SciBase
Triveni Bio Advances Bispecific Antibody TRIV-573 for Patients with Atopic Dermatitis#United_States#Atopic_Dermatitis#Triveni_Bio#TRIV-573#Watertown,_Massachusetts
Triveni Bio Advances Bispecific Antibody TRIV-573 for Patients with Atopic Dermatitis
Triveni Bio has initiated a Phase 1 clinical trial for TRIV-573, a bispecific antibody designed to treat atopic dermatitis through dual targeting mechanisms.
third-news.com
May 18, 2026 at 11:35 AM
Triveni Bio Advances Bispecific Antibody TRIV-573 for Patients with Atopic Dermatitis#United_States#Atopic_Dermatitis#Triveni_Bio#TRIV-573#Watertown,_Massachusetts
Bambusa Therapeutics Completes Enrollment in Pivotal Clinical Trial for BBT001 in Atopic Dermatitis#United_States#Boston#Atopic_Dermatitis#Bambusa_Therapeutics#BBT001
Bambusa Therapeutics Completes Enrollment in Pivotal Clinical Trial for BBT001 in Atopic Dermatitis
Bambusa Therapeutics has successfully completed patient enrollment for its Phase 1b/2a study of BBT001, targeting severe atopic dermatitis. Topline results are expected in mid-2026.
third-news.com
April 30, 2026 at 12:16 PM
Bambusa Therapeutics Completes Enrollment in Pivotal Clinical Trial for BBT001 in Atopic Dermatitis#United_States#Boston#Atopic_Dermatitis#Bambusa_Therapeutics#BBT001
Emerging Needs in Senior Atopic Dermatitis Care Highlighted by New Survey Results#Japan#Tokyo#Atopic_Dermatitis#Cosmo_Lab#Cosmo_Health
Emerging Needs in Senior Atopic Dermatitis Care Highlighted by New Survey Results
A recent survey reveals the challenges and improvement needs faced by seniors dealing with atopic dermatitis, shedding light on their experiences and attitudes.
third-news.com
April 8, 2026 at 3:03 AM
Emerging Needs in Senior Atopic Dermatitis Care Highlighted by New Survey Results#Japan#Tokyo#Atopic_Dermatitis#Cosmo_Lab#Cosmo_Health
American Academy of Dermatology Releases Pioneering Guidelines for Managing Pediatric Atopic Dermatitis#United_States#Rosemont#Atopic_Dermatitis#American_Academy_of_Dermatology#Pediatric_Eczema
American Academy of Dermatology Releases Pioneering Guidelines for Managing Pediatric Atopic Dermatitis
The American Academy of Dermatology has unveiled its first-ever guidelines for pediatric atopic dermatitis, focusing on preventive measures and treatment options to enhance care for affected children.
third-news.com
April 7, 2026 at 7:33 PM
American Academy of Dermatology Releases Pioneering Guidelines for Managing Pediatric Atopic Dermatitis#United_States#Rosemont#Atopic_Dermatitis#American_Academy_of_Dermatology#Pediatric_Eczema
Bambusa Therapeutics Showcases Promising Trial Outcomes for BBT001 at AAD 2026#United_States#Denver#Atopic_Dermatitis#Bambusa_Therapeutics#BBT001
Bambusa Therapeutics Showcases Promising Trial Outcomes for BBT001 at AAD 2026
Bambusa Therapeutics presented impressive Phase 1 trial results for BBT001 at the AAD 2026 Annual Meeting, demonstrating its potential for treating atopic dermatitis.
third-news.com
April 1, 2026 at 2:23 PM
Bambusa Therapeutics Showcases Promising Trial Outcomes for BBT001 at AAD 2026#United_States#Denver#Atopic_Dermatitis#Bambusa_Therapeutics#BBT001